Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.
Abstract
Purpose: Approximately 20% of patients with RAS wild-type metastatic colorectal cancer (mCRC) experience objective responses to the anti-EGFR antibody cetuximab, but disease eradication is seldom achieved. The extent of tumor shrinkage correlates with long-term outcome. We aimed to find rational combinations that potentiate cetuximab efficacy by disrupting adaptive dependencies on antiapoptotic molecules (BCL2, BCL-XL, MCL1). Experimental Design: Experiments were conducted in patient-derived xenografts (PDX) and organoids (PDXO). Apoptotic priming was analyzed by BH3 profiling. Proapoptotic and antiapoptotic protein complexes were evaluated by co-immunoprecipitation and electroluminescence sandwich assays. The effect of combination therapies was assessed by caspase activation in PDXOs and by monitoring PDX growth. Results: A population trial in 314 PDX cohorts, established from as many patients, identified 46 models (14.6%) with appreciable (>50% tumor shrinkage) but incomplete response to cetuximab. From these models, 14 PDXOs were derived. Cetuximab primed cells for apoptosis, but only concomitant blockade of BCL-XL precipitated cell death. Mechanistically, exposure to cetuximab induced upregulation of the proapoptotic protein BIM and its sequestration by BCL-XL. Inhibition of BCL-XL resulted in displacement of BIM, which was not buffered by MCL1 and thereby became competent to induce apoptosis. In five PDX models, combination of cetuximab and a selective BCL-XL inhibitor triggered apoptosis and led to more pronounced tumor regressions and longer time to relapse after treatment discontinuation than cetuximab alone. Conclusions: In mCRC tumors that respond to cetuximab, antibody treatment confers a synthetic-lethal dependency on BCL-XL. Targeting this dependency unleashes apoptosis and increases the depth of response to cetuximab.
Overview
CoChat Summary
TL;DR
In patient-derived models of metastatic colorectal cancer, cetuximab primes cells for apoptosis and upregulates BIM, but BCL-XL sequesters BIM and prevents cell death. Adding BCL-XL blockade unleashes apoptosis, deepens cetuximab response, and delays relapse in PDX models.
Key findings
- In a population trial of 314 mCRC PDXs, only 46 models (14.6%) showed >50% mean tumor volume reduction after 3 weeks of cetuximab; all cetuximab-sensitive models lacked KRAS, NRAS, and BRAF resistance-driving mutations.
- Cetuximab increased apoptotic priming in PDXOs and upregulated BIM, which was preferentially sequestered by BCL-XL; selective BCL-XL inhibition with A-1331852 or navitoclax plus cetuximab triggered massive caspase 3/7 activation in 14 cetuximab-sensitive PDXOs, whereas the BCL2 inhibitor venetoclax did not enhance cetuximab.
- In five cetuximab-sensitive PDXs, cetuximab plus A-1331852 produced deeper tumor shrinkage in two models, reduced cancer cell density in others, and led to longer time to relapse after treatment discontinuation than cetuximab alone.
- In cetuximab-resistant PDXOs, cetuximab did not induce BIM upregulation, and adding cetuximab to BCL-XL inhibition was inconsequential.
Methods
- Patient-derived xenografts (PDX) and organoids (PDXO) from mCRC; a 314-PDX population trial identified cetuximab-responsive models, 14 PDXOs were derived, and five PDX models were used for in vivo combination testing.
- Dynamic BH3 profiling measured apoptotic priming; co-immunoprecipitation and Meso Scale Discovery assays quantified BIM:BCL-XL and BIM:MCL1 complexes; viability, caspase 3/7, qRT-PCR, IHC, and morphometric analyses were used.
- Statistical analyses included two-tailed Welch t test, one-way ANOVA with Šidák correction, Spearman correlation, and log-rank (Mantel–Cox) test, with significance set at P < 0.05.
Limitations
- The paper states it did not explore the reasons underlying modulation of MCL1:BIM stoichiometry by navitoclax and cetuximab.
- The paper notes that caliper-based tumor measurements are not precise with very small masses.
- The paper states that navitoclax development faces obstacles due to high incidence of on-target thrombocytopenia from BCL-XL inhibition in platelets; evident from the text, the in vivo combination efficacy was assessed in five PDX models and remains preclinical.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
0 Valid · 0 Not valid · 20 Not checked · 87 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cetuximab-induced apoptotic priming prompted a specific dependency on BCL-XL, but not on BCL2, which proved to be poorly expressed in mCRC organoids both basally and after cetuximab treatment.”
§ Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the addition of cetuximab was inconsequential (Fig. 2A and C, bottom; Supplementary Fig. S2).”
§ Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer > Results > Selective BCL-XL inhibition potentiates the therapeutic effect of EGFR blockade by unleashing apoptosis in cetuximab-sensitive organoids
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we observed a modest but significant correlation between the extent of response to A-1331852 plus cetuximab combination therapy and the ratio of BCL-XL to BIM mRNA expression (Supplementary Fig. S3).”
§ Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer > Results > Selective BCL-XL inhibition potentiates the therapeutic effect of EGFR blockade by unleashing apoptosis in cetuximab-sensitive organoids
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After 48 hours of treatment, overall cell numbers were more markedly reduced by combination therapy than by single-agent cetuximab or navitoclax (Fig. 2A, top; Supplementary Fig. S2)”
§ Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer > Results > Selective BCL-XL inhibition potentiates the therapeutic effect of EGFR blockade by unleashing apoptosis in cetuximab-sensitive organoids
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Lower expression of BCL2 in comparison with BCL-XL and MCL1 was also observed at the transcriptional level, as evaluated by qRT-PCR in our representative panel of 14 PDXOs (Supplementary Fig. S1B).”
§ Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer > Results > EGFR blockade increases apoptotic priming and BIM:BCL-XL interaction
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
58 more claims
Create a free account to see all 107 claims and to verify the 32 references still open.
- It may state two separate claims as one. 35
- Probably not a substantial claim. 13
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer > Abstract > Results:
“In five PDX models, combination of cetuximab and a selective BCL-XL inhibitor triggered apoptosis and led to more pronounced tumor regressions and longer time to relapse after treatment discontinuation than cetuximab alone.”
§ Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer > Results > Combined EGFR/BCL-XL blockade reduces residual disease in vivo
“Of note, the two models in which combination therapy did not further regress palpable masses (CRC1272 and CRC0322) were both extremely sensitive to cetuximab alone (mean tumor volume changes of −95.28% and −89.92%, respectively).”
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900 · cited 1×
“For example, the selective BCL2-inhibitor venetoclax (ABT-199) has been approved for use in chronic lymphocytic leukemia and acute myeloid leukemia on the basis of its excellent clinical activity (15, 16).”
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“However, although response rates are clinically meaningful, anti-EGFR therapy only exceptionally leads todisease eradication, and patients ultimately recur (5).”
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111 · cited 1×
“…activators induce the oligomerization of pore-forming effectors (namely, BAX and BAK), resulting in mitochondrial outer membrane permeabilization (MOMP) and mitochondrial release of apoptogenic molecules like cytochrome c, with subsequent caspase activation and cell death (12).”
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 3×
“…therapies aimed to increase the depth of response to EGFR inhibition, we evaluated the population-level distribution of tumor response to single-agent cetuximab in a collection of 314mCRC PDXs, established from as many patients, part of which had been used in previous studies(10,25,27,29,30).”
Self-citation
Cited by
PDX models for functional precision oncology and discovery science
Blanchard, Z., Brown, E. A., Ghazaryan, A., & Welm, A. L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00779-3 · Cited by 71
Patient‐derived xenograft models in pan‐cancer: From bench to clinic
Li, J., Gu, A., Tang, N., Zengin, G., Li, M., & Liu, Y. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20250016 · Cited by 69
Kwon, J., Oh, J.-S., Seok, S. H., An, H., Lee, Y. J., Lee, N. Y., Ha, T., Kim, H. A., Yoon, G. M., Kim, S. E., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01857-0 · Cited by 34
Abd-Rouf, M. S. K., Adigun, P. O., Faniyi, A. J., Oladapo, B. G., Abd-Rouf, A. B., Alalade, E. O., Awopejo, T. E., Adegoke, O. S., Oyekanmi, T. T., Jamiu, A. B., et al. (2024) · International Journal of Science Research and Technology · doi:10.15662/ijsrat.2024.0703003 · Cited by 26
Sogari, A., Rovera, E., Grasso, G., Mariella, E., Reilly, N. M., Lamba, S., Mauri, G., Durinikova, E., Vitiello, P. P., Lorenzato, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101376 · Cited by 17
Self-citation
Metadata
- Authors
- Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., Grassi, E., Trusolino, L., & Bertotti, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- 3Mauriziano Umberto I Hospital, Torino, Italy.
- Corresponding author
- Trusolino, Livio
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2023-01-09
- Volume
- 29
- Issue
- 6
- Pages
- 1102-1113
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC10011886
- OpenAlex
- W4313830048
- Semantic Scholar
- b848a564c36380c81197e5812d02ae0c36a36a47
- Cited by
- 30
- References
- 50
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 21
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by-nc-nd)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (Investigator Grant 22802, 5x1000 grant 21091, AIRC/CRUK/FC AECC Accelerator Award 22795, Investigator Grants 20697)
- HORIZON EUROPE European Research Council (Consolidator Grant 724748 BEAT)
- Horizon 2020 Framework Programme (754923 COLOSSUS, 731105 EDIReX)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- synthetic lethality, BCL-XL inhibition, cetuximab, metastatic colorectal cancer, EGFR inhibition, building information modeling, Mcl-1, apoptosis, patient-derived xenografts, colorectal cancer organoids, combination therapy, depth of response, RAS wild-type
- MeSH terms
- Cetuximab, Colonic Neoplasms, Humans, Neoplasm Recurrence, Local, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, Apoptosis Regulatory Proteins, bcl-X Protein, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-2550
- The paper
- Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., Grassi, E., Trusolino, L., & Bertotti, A. (2023). Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-2550
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.